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Abstract
All skeletal muscle progenitor cells in the body derive from the dermomyotome, the dorsal epithelial domain of developing
somites. These multipotent stem cells express Pax3, and this expression is maintained in the myogenic lineage where Pax3
plays an important role. Identification of Pax3 targets is therefore important for understanding the mechanisms that
underlie the onset of myogenesis. In a microarray screen of Pax3-GFP sorted cells, with analysis on Pax3 gain and loss of
function genetic backgrounds, we identify Dmrt2, expressed in the dermomyotome, as a Pax3 target. In vitro gel shift
analysis and chromatin immunoprecipitation with in vivo extracts show that Pax3 binds to a conserved 286 bp sequence,
situated at 218 kb from Dmrt2. This sequence directs reporter transgene expression to the somite, and this is severely
affected when the Pax3 site is mutated in the context of the locus. In Dmrt2 mutant embryos, somite maturation is
perturbed and the skeletal muscle of the myotome is abnormal. We now report that the onset of myogenesis is also
affected. This depends on activation, in the epaxial dermomyotome, of the myogenic determination gene, Myf5, through its
early epaxial enhancer. This sequence contains sites that bind Dmrt2, which belongs to the DM class of DNA–binding
proteins. Mutation of these sites compromises activity of the enhancer in transgenic embryos where the reporter transgene
is under the control of the Myf5 epaxial enhancer. Transactivation of this site by Dmrt2 is demonstrated in vitro, and
conditional overexpression of Dmrt2 in Pax3 expressing cells in the somite confirms the role of this factor in the activation of
Myf5. These results reveal a novel genetic network, comprising a Pax3/Dmrt2/Myf5 regulatory cascade that operates in stem
cells of the epaxial dermomyotome to initiate skeletal muscle formation.
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Introduction
The Pax family of transcriptional regulators play key roles in the
onset of organogenesis and cell lineage specification during
development [1]. Pax3 and Pax7 regulate skeletal muscle
formation. Skeletal muscle progenitors in the trunk and limbs of
vertebrates derive from somites, from the dorsal compartment
known as the dermomyotome. In the mouse embryo, Pax3 is
expressed throughout this epithelial structure, whereas Pax7
expression is restricted to the central domain. Myogenesis is
initiated by the delamination of Pax3 positive cells from the edges
of the dermomyotome; at certain axial levels, cells from the
hypaxial domain migrate from the somite, before activating the
myogenic determination genes Myf5 and MyoD, whereas other
cells, most notably in the epaxial domain, have already activated
Myf5 and immediately differentiate, on delamination, to form the
first skeletal muscle of the epaxial myotome. Transcription of Myf5
at this site depends on an early epaxial enhancer, which lies at
25.5 kb from the gene [2,3]. This sequence is regulated by Shh
[4–6] and by canonical Wnt signalling [6] from the adjacent axial
structures, acting through Gli and TCF binding sites. Subsequent-
ly, as the somite matures, the central dermomyotome loses its
epithelial structure and cells that are positive for Pax3 and Pax7
enter the underlying muscle masses. These provide an essential
population of muscle stem cells for all subsequent muscle growth.
In Pax3
2/2; Pax7
2/2 double mutants, these cells fail to activate
myogenic determination genes and many of them die [7]. In the
absence of Pax3 alone, cell death is also observed at the extremities
of the dermomyotome, where it is most evident in the hypaxial
domain [1].
Pax3 target genes that are important for the onset of myogenesis
are beginning to be identified. A classic example is provided by the
gene encoding c-Met, a receptor required for delamination and
migration of muscle progenitor cells [8]. More recently, a Myf5
regulatory sequence required for activation of this myogenic
determination gene in the limb and hypaxial somite has been
identified as a direct Pax3 target [9]. The second myogenic
determination gene, MyoD, has been shown to be a target of Pax3/
7 in a myogenic cell line and in postnatal muscle progenitor cells
[10] and indeed other Pax7 [11,12] targets have been identified in
PLoS Genetics | www.plosgenetics.org 1 April 2010 | Volume 6 | Issue 4 | e1000897this cellular context. Activation of myogenic determination genes
leads to entry into the myogenic programme, which is accompa-
nied by down-regulation of Pax3/7, to which microRNAs
contribute [13]. However, maintenance of a muscle stem cell
population is essential in the growing organism and this is achieved
through signalling systems that maintain a balance between self-
renewal and differentiation [14]. In the context of FGF signalling,
Pax3 directly regulates Fgfr4 and acts genetically upstream of other
components of the pathway also, such as Sprouty1, to control self-
renewal versus differentiation of Pax3 positive muscle progenitors
[15].
In order to identify further Pax3 target genes acting at earlier
stages within the dermomyotome, we have performed a micro-
array screen that has led to the identification of Dmrt2. This gene
family was first characterized as doublesex in Drosophila [16–18] and
as mab-3 in C.elegans [19], where these genes play important roles in
sex determination [20,21]. Vertebrate homologues have since
been identified, some of which also play a role in sexual
development [22]. However Dmrt genes are also expressed outside
the gonads and have been implicated in other developmental
processes. Dmrt2/Terra is expressed during somitogenesis in
vertebrates [23], where transcripts are present in the presomitic
mesoderm (PSM) and then confined to the dermomyotome of
somites. In the chick embryo, Terra is expressed symmetrically in
the PSM, but has a transient asymmetrical expression around the
node, implicating it in left-right axis determination and normal
development of bilateral somites through interaction with the
segmentation clock, as indicated by morpholino experiments in
zebrafish [24]. Mouse embryos lacking Dmrt2 show somite
patterning defects, culminating in malformed ribs and sternum
leading to postnatal death due to respiratory problems [25]. Such
malformations are often associated with abnormal dermomyotome
and myotome development [1] and indeed Dmrt2
2/2 embryos
have morphological defects in these somite compartments, with
perturbation of the expression of myogenic markers reported at
E10.5 and E11.5. In Dmrt2 and Pax3 compound mutants
perturbations in myogenesis were also observed [26], as evidenced
by muscle differentiation markers at E10.5. However cell death in
the absence of Pax3 [1] complicates the interpretation.
The molecular function of Dmrt2 has not been investigated.
Dmrt proteins are characterised by the DM domain, an
intertwined Zn finger-like motif that interacts with the minor
groove of DNA [27]. The conserved DM domains of mammalian
Dmrt factors bind to similar DNA consensus sequences [28].
Drosophila Dsx
m acts as a transcriptional activator whereas Dsx
F
has repressor function [29]. When human DMRT1 is fused to the
VP16 activation domain, transactivation through the consensus
DMRT1 binding sequence is observed, however DMRT1 alone
did not show much activity [28]. Regulation of the Dmrt2 gene,
present in a cluster with Dmrt1, 3 in mice, has not been examined,
although the human DMRT2 gene has been shown to encode
alternatively spliced transcripts [30].
In this report, we identify Dmrt2 as a target of Pax3, acting
directly through a regulatory sequence that directs expression in
the somite. We show that Dmrt2, in turn, acts on the epaxial
enhancer of Myf5. Perturbation of this regulatory network,
functioning in the dermomyotome, has consequences for the
onset of myogenesis.
Results
In a screen designed to detect Pax3 targets in the dermomyotome
of interlimb somites at E9.5, this region of the somite was dissected
from Pax3
GFP/+heterozygoteandPax3
PAX3-FKHR-IRESnlacZ/GFPgainof
function embryos [31]. After dissociation, GFP positive cells were
separated by flow cytometry. Microarray comparisons of the two
classes of samples led to identification of a series of sequences that
are up- or down-regulated in the presence of PAX3-FKHR, a
constitutively active form of the Pax3 transcription factor [31].
Among these sequences, Dmrt2 was up-regulated 1.87 fold (data not
shown).
Dmrt2 is transcribed in mouse somites (Figure 1), as previously
reported [25]. Expression is detected as a band in presomitic
mesoderm (S0) and in the first somites at E8.5, where transcripts
accumulate in the epaxial domain, as shown for immature caudal
somites at E9.5 (C0). Sections of a Pax3
IRESnlacZ/+ embryo at this
stage (Figure 1F) show that Dmrt2 expression is confined to the
Pax3 positive dermomyotome of the somite, in the epaxial domain
of the most immature caudal somites (Figure 1G), and then
throughout this epithelium in more mature somites (Figure 1H).
Already, at this stage, the most mature anterior somites (Figure 1I)
are beginning to lose Dmrt2 expression at the epaxial and hypaxial
extremities of the dermomyotome. This is detected also by whole
mount in situ hybridization at E9.5 (Figure 1C and 1C9) and at
E10.5 (Figure 1D), when labelled cells are also detectable in the
mesodermal core of the 1st and 2nd branchial arches and in the
forelimb bud, to which myogenic progenitor cells have begun to
migrate from the somites [1]. By E11.5 (Figure 1E), Dmrt2
transcripts are only detectable in caudal somites.
The expression of Dmrt2 is similar in Pax3
GFP/+ heterozygote
embryos (Figure 2A and 2D–2F) to that in wild type embryos
(Figure 1). However Dmrt2 expression levels are higher in the
dermomyotome of Pax3
PAX3-FKHR-IRESnlacZ/GFP gain of function
embryos (Figure 2B and 2G–2I), whereas they are notably lower in
Pax3
Pax3-En-IRESnlacZ/+ embryos, where the presence of a fusion
protein in which the DNA binding domain of Pax3 is fused to the
repression domain of Engrailed, results in a partial loss of function
phenotype [9], attenuating the cell death seen in the absence of
Pax3. Diminution of Dmrt2 expression is also seen in Pax3 mutant
embryos at E9.25 (Figure S1), prior to extensive cell death.
Maintenance of Dmrt2 expression in the central dermomyotome
may reflect the expression of Pax7 in this domain. These results
confirm that Dmrt2 lies genetically downstream of Pax3.
In order to see whether Dmrt2 is a direct Pax3 target, we
examined the Dmrt2 locus on mouse chromosome 19, which
Author Summary
It is well established that skeletal muscle derives from
segmented structures called somites that form on either
side of the axis of the embryo. The part of the somite that
contains muscle stem cells is called the dermomyotome.
These cells express the transcription factor Pax3, which
regulates muscle stem cell behaviour. We now show that
the Dmrt2 gene, also expressed in the dermomyotome, is
directly controlled by Pax3. Since Dmrt2 has been
implicated in maintaining the integrity of the dermomyo-
tome, this therefore indicates an upstream role for Pax3
in this structure as well as in controlling cells that form
skeletal muscle. Furthermore Dmrt2 directly regulates
early activation of the myogenic determination gene,
Myf5, required for the formation of the first skeletal
muscle in the somite. This is a novel function for Dmrt2
and shows that this transcription factor controls both
structure and cell fate. Our results reveal a Pax3/Dmrt2/
Myf5 regulatory cascade through which Pax3 orchestrates
the onset of myogenesis in the muscle stem cells of the
dermomyotome.
A Pax3/Dmrt2/Myf5 Regulatory Cascade
PLoS Genetics | www.plosgenetics.org 2 April 2010 | Volume 6 | Issue 4 | e1000897Figure 1. The expression of Dmrt2, visualised by whole mount in situ hybridization. Embryos were hybridized with a Dmrt2 RNA probe. (A)
an E8.5 embryo, (B) an E9.0 embryo, (C, F) E9.5 embryos, (D) an E10.5 embryo, (E) an E11.5 embryo. C9 and C0 are magnified views of C. Dmrt2
transcripts are present in all somites until E11.5 when they are only detected caudally. (F) A Pax3
IRES-nlacZ/+ embryo at E9.5 hybridized with a Dmrt2
probe (blue) and treated with Red-gal to reveal b-galactosidase (b-gal) expression from the Pax3
IRES-nlacZ allele (red). Dmrt2 expression was also
detected in proximal forelimb buds and branchial arches (arrowheads in D). (G–I) Transverse sections of the embryos shown in F. Equivalent axial
levels are also indicated in C9 and C0. White dotted lines outline the dermomyotome. Dmrt2 expression is observed in the epaxial domain of immature
somites (C0, G), and then throughout the Pax3 positive dermomyotome (C9, H). In more mature anterior somites, the expression of Dmrt2 in the
epaxial and hypaxial edges of the dermomyotome has decreased (I). S0, presomitic mesoderm prior to the first somite; NT, neural tube; Ep, epaxial
somite; Hyp, hypaxial somite.
doi:10.1371/journal.pgen.1000897.g001
Figure 2. The expression of Dmrt2 is controlled by Pax3. (A–C) Whole mount in situ hybridization with a Dmrt2 probe of Pax3
GFP/+ (A),
Pax3
PAX3-FKHR-IRESnlacZ/GFP (Pax3
PAX3-FKHR/GFP, B) and Pax3
Pax3-En-IRESnlacZ/+ (Pax3
Pax3-En/+, C) embryos at E9.5. Pax3 expression is shown as GFP fluorescence
(inserts in A, B), or as Salmon-gal staining (insert in C) of trunk somites. A9–C9 show enlargements of the posterior somite regions used for sections.
(D–L) Sections at equivalent axial levels showing Dmrt2 transcripts in the dermomyotome of control Pax3
GFP/+ (D–F), gain of function Pax3
PAX3-FKHR/GFP
(G–I) or partial loss of function Pax3
Pax3-En/+ (J–L) embryos. Dmrt2 transcripts are higher in gain of function embryos, where they are now detectable
throughout the dermomyotome, whereas when Pax3 activity is altered they are barely detectable in the epaxial domain of immature somites (J) and
detectable in a restricted region of more mature somites (L). Arrowheads indicate the full extent of the dermomyotome. PSM, presomitic mesoderm;
S0, PSM prior to the first somite.
doi:10.1371/journal.pgen.1000897.g002
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conserved between species (Figure 3A). A conserved 286 bp region
at about 218 kb from the Dmrt2 gene attracted our attention. This
region has five putative Pax3 binding sites (Figure 3B). Electro-
phoretic mobility gel shift assays with oligonucleotides encom-
passing these sites and in vitro synthesized Pax3 protein showed that
site2 binds Pax3, a result confirmed by a super-shift experiment
with a Pax3 antibody (Figure 3C). Chromatin immunoprecipita-
tion of embryo extracts at E9.5 demonstrated that Pax3 binds
specifically to the 286 bp sequence at 218 kb from the Dmrt2 gene
in vivo. The function of the 286 bp sequence was tested in
transgenic embryos. It directs transgene expression in the
dermomyotome, where the endogenous gene is expressed, with
additional ectopic expression in the ventral somite (Figure 3E).
Mutation of Pax3 site2 in the 286 bp sequence interferes with the
expression of the transgene in the dermomyotome (Figure 3F).
Other conserved regions, notably at +20 kb and +37 kb did not
direct reporter gene expression in transgenic embryos. A BAC
transgenic analysis had shown that 150 kb of 59 and 50 kb of 39
genomic sequence flanking the Dmrt2 gene directed somitic
expression in transgenic embryos. When the Pax3 binding site in
the 286 bp sequence was mutated in the context of this BAC,
somitic expression was severely affected (Figure S2). This result
therefore indicates that the Pax3 site within this sequence plays an
important role in the regulation of the Dmrt2 gene.
Dmrt2 has been implicated in somite patterning, with
morphological abnormalities reported in mature somites from
E10.5 [25]. These include abnormal expression of myotomal
markers. Since Dmrt2 is first expressed in the epaxial dermomyo-
tome where activation of the myogenic determination gene, Myf5,
initiates the onset of myogenesis [1], we examined Myf5 expression
in Dmrt2 mutant embryos. Myf5 activation in the epaxial domain is
retarded in the absence of Dmrt2. This is detectable on whole
mount in situ hybridization (Figure 4A and 4B). On sections of
somites at equivalent axial levels, Myf5 expression is reduced. The
delay in the colonisation of the myotome reflects the reduction in
Myf5 transcription in the epaxial domain. (Figure 4D and 4F). This
perturbation in Myf5 activation has consequences for myogenesis,
as evidenced by the delay in expression of the gene for the
myogenic differentiation factor, myogenin (Figure 4G and 4H), in
the absence of Dmrt2. Pax3 transcription, on the other hand, is not
reduced at the onset of somitogenesis (Figure 4I and 4J).
The initiation of Myf5 expression in the somite depends on an
early epaxial enhancer [2,3]. This element, used here in its
extended form (Myf5-EpExt; [6]), is regulated by Gli and TCF
binding sites, targets of Hedgehog and canonical Wnt signalling.
The enhancer contains four sites that are close to the consensus for
Dmrt2 binding ([28], Figure 5A). Of these, sites 1, 3 and 4 bind
Dmrt2, as shown by electrophoretic mobility shift assays
(Figure 5B–5D). This is specific since it is abolished by competition
with the Myf5 sequence, but not by this sequence with mutations in
the Dmrt2 binding sites (Figure 5C). No good antibodies are
available for Dmrt2 detection, so we used a human influenza
hemagglutinin (HA) tagged version of the protein, and anti-HA
antibodies to show that the complex is disrupted (Figure 5D). The
Myf5-EpExt enhancer, with a TK or Myf5BA promoter region
drives nlacZ transgene expression in somites. When the Dmrt2 sites
are mutated in the Myf5-EpExt enhancer, this expression is very
reduced in newly forming somites and is perturbed or absent in
more mature somites (Figure 5E and 5F). Transactivation of the
Myf5-EpExt enhancer by Dmrt2 was shown by co-transfection
experiments in NIH3T3 cells, with this enhancer driving a
luciferase reporter and increasing amounts of a Dmrt2 expression
vector; mutation of the Dmrt2 sites (1,3,4) in the Myf5-EpExt
sequence showed that activity depends on Dmrt2 binding
(Figure 6A). Strong transactivation by Dmrt2 was also seen in
HEK293 cells (results not shown). In order to look at Dmrt2
activation in vivo, a transgene was constructed in which expression
of a sequence encoding Dmrt2, under the transcriptional control
of a strong universal CAG promoter, depends on Cre recombinase
removal of an intervening CAT sequence. When crossed with a
PGK-Cre line [32], Dmrt2 expression is seen throughout the embryo
(Figure 6C, the left hand embryo), as also evidenced by expression
of the Tomato red reporter (Figure 6C9). When crossed with a
Pax3
Cre/+ line [33], the Dmrt2 transgene is transcribed at sites of
Pax3 expression, including the somites and dorsal neural tube
(Figure 6D), where Tomato red coloration is also detected
(Figure 6D9). Expression of the endogenous Myf5 gene was
monitored in these transgenic embryos at E9.5 (ss 23). When the
Dmrt2 transgene is activated by Pax3-Cre, Myf5 expression is more
extensive in the newly formed somites (Figure 6E) than in the
control embryo (Figure 6H). Myogenin transcripts are also more
widely expressed (Figure 6F and 6I) and sections of an immature
somite show premature presence of assembled laminin, which
marks the myotome basement membrane (Figure 6G, compared
to Figure 6J). Together, these data indicate that myogenesis is
accelerated in these embryos, leading to an earlier entry and
organisation of cells in the myotomal space. The effect on Myf5
expression is also seen when the Dmrt2 transgene is expressed in
Myf5
nlacZ/+ mice (Figure 6K, compared to Figure 6L) and sections
show that Myf5 is now ectopically expressed in the central/
hypaxial dermomyotome in the presence of Pax3-Cre (Figure 6K9
and 6K0 compared to Figure 6L9 and 6L0). A similar result was
seen with PGK-Cre (Figure S3). This therefore demonstrates that
Dmrt2 activates the Myf5 gene in vivo in the somite, leading to
ectopic expression. Acceleration of the onset of myogenesis and
myotome formation are probably the consequence of over-
expression of Dmrt2 and over-activation of the epaxial enhancer
of Myf5.
Discussion
We establish a genetic network that is initiated in the
dermomyotome by Pax3 regulation of Dmrt2 and which, through
Dmrt2 regulation of Myf5, orchestrates the onset of myogenesis in
the myotome. This direct transcriptional cascade and further
genetic targets discussed in this paper are presented schematically
in Figure 7.
Our demonstration that Dmrt2 is a Pax3 target was initially
based on a genetic analysis that showed up-regulation of this gene
in the presence of PAX3-FKHR. This transcriptional activator of
Pax3 target genes may introduce a bias due to the FKHR domain,
however down-regulation of Dmrt2 in the presence of the Pax3-
Engrailed fusion protein and in the absence of Pax3 reinforces the
interpretation. This is confirmed by the identification of a Pax3
dependent regulatory sequence, located at 18 kb 59 of the Dmrt2
gene, which directs transgene expression to the somite. Mutation
of the Pax3 site shown to bind this factor in vitro and in vivo,
abolishes most of the activity in the dermomyotome. Since Pax7
can replace Pax3 in the trunk [34], it is probable that this site also
binds Pax7. Indeed in Pax3 mutants, Dmrt2 continues to be
expressed in the remaining dermomyotome [26], where Pax7
prevents cell death in the absence of Pax3 [1]. Expression of the
transgene is not confined to the dermomyotome, suggesting that
the 286 bp element also responds to factors in the ventral somite,
where transcription of the endogenous gene is repressed by other
regulatory sequences. Dmrt2 is present in a locus that includes
Dmrt1 and Dmrt3. The latter lies about 30 kb 59 of the 286 bp
A Pax3/Dmrt2/Myf5 Regulatory Cascade
PLoS Genetics | www.plosgenetics.org 4 April 2010 | Volume 6 | Issue 4 | e1000897Figure 3. A conserved 286 bp element 59 of the Dmrt2 gene directs Pax3-dependent expression in the somite. (A) A schematic
representation of the mouse Dmrt genomic locus showing overall sequence conservation (blue bars) between human, rat, chicken and Xenopus (green
bars). (B) The nucleotide sequence of the conserved 286 bp Dmrt2 element (red circle in A) in mouse (the position on ch19; 25728951 to 25729236,
about 18 kb 59 of Dmrt2) and comparison with a homologous region of human, chick and Xenopus genomes, with asterisks indicating conserved
nucleotides between all these species. Five putative Pax3 binding sites are framed in black and red. (C) Electrophoretic mobility shift assays (EMSA)
performed with oligonucleotides conjugated with biotin, containing putative Pax3 binding sites (1–5) as indicated in (B), incubated with extracts of
HEK293 cells, with (+) or without (2) a Pax3 expression vector, or oligonucleotides without biotin (+dsDNA), including mutated oligonucleotides (+mut-
dsDNA). ThePax3siteinthe145 bp regulatory element at 257.5 kb from theMyf5 geneprovides a positive control (Myf5-145; [9]).Significantbinding is
seen on site2 when Pax3 protein is present. For supershift assays, monoclonal Pax3 antibody (DSHB) was used (+anti-Pax3); +anti-Flag provides a
negative control. Arrowheads show the band due to binding of the Pax3 protein. NS; non-specific. (D) Chromatin immunoprecipitation (ChIP) analysis of
Pax3 binding to the 286 bp sequence in vivo was performed with chromatin prepared from somites of E9.5 embryos (without head, neural tube, and
internal tissues). Upper panels show the evaluation of sheared genomic DNA (1/10 input) with two sets of Dmrt2 primers, for the potential regulatory
sequence (286) and for an upstream control sequence (+20 k) without Pax3 binding sites (results not shown), in left and right panels respectively. As an
additionalpositiveornegativecontrol,wholegenomeshearedgenomicDNA,with(wholegenome) orwithoutproteinaseK(NoProteinaseK)treatment
is shown(Inthe absence ofproteinaseK cross-linked chromatinblocksthePCRreaction).Lowerpanelsshow ChIP(IP)withtwodifferent Pax3 antibodies
(aPax3, Bajard et al. (2006), Lagha et al. (2008)) and control rabbit serum. Left lower bands indicate Pax3 binding to the 286 bp sequence, not seen with
thecontrol+20 kbsequence(rightpanels).(E)Atransienttransgenicembryo(E9.5)withthe286 bpDmrt2fragment,fusedtotheTKpromoterandnlacZ
reporter shows dermomyotome expression. (F) The transgene, with mutated Pax3 binding site2, shows loss of b-galactosidase activity in the
dermomyotome (F9), but some ectopic expression in the myotome and ventral somite (F0), seen in more mature somites in the non-mutated transgenic
embryo (E0). Observations on transgenic embryos are summarised in Table 1.
doi:10.1371/journal.pgen.1000897.g003
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there is no indication that this regulatory element directs any
aspect of Dmrt3 expression, which is characteristically seen at sites
in the head [35,36] for example, where no labelling with the
Dmrt2-286-TKnlacZ transgene is observed. Other regulatory
regions, namely 2.6 kb immediately 59 of Dmrt1 which directs
transgene expression to the testis [37] or a highly conserved
sequence between Dmrt1 and Dmrt3, associated with XY sex
reversal in humans [38], which directs Dmrt3-like transgene
expression, also show regulatory properties characteristic of the
adjacent downstream gene only.
It is well established that the DM domains of Dmrt2 factors bind
to a similar consensus sequence [28], however direct target genes
have not been identified. We now show that the Myf5 gene is
targeted by Dmrt2 through the expected DM consensus sequence.
The transcriptional activity of mammalian Dmrt factors is not well
defined, in contrast to Drosophila Dsx which acts as a transcrip-
tional activator or repressor, when produced from a male or
female allele, respectively [29]. We demonstrate that Dmrt2
functions as a transcriptional activator on a DM consensus binding
site in the Myf5 early epaxial element. This was observed in assays
with the NIH3T3 fibroblast cell line, and with HEK293 cells in
which transcriptional activity of Dmrt1 was not detectable under
conditions in which a Dmrt1-VP16 fusion protein transactivated a
luciferase reporter through DM sites [28]. Our transgenic
experiments which lead to Dmrt2 over-expression in vivo also
point to the action of this factor as an activator of Myf5 expression.
Dmrt2 mutant phenotypes in which somite disorganisation and
effects on myogenesis had been documented previously, focussed
on E10.5 and E11.5 embryos [25,26]. We observed that Dmrt2
transcription begins to be down-regulated from E10.5 and
transcripts are no longer detectable in most somites by E11.5.
The muscle recovery noted in Dmrt2 mutants at later stages [25] is
probably due to the invasion of the underlying muscle by Pax3/7
positive cells, from the central dermomyotome, which takes place
from E10.5 [7]. Indeed in Dmrt2 mutants at E10.5, the absence of
apically polarised N-cadherin, in the dermomyotome ([25],
Figure 4), may indicate de-epithelialization and premature
disaggregation of the central domain which is the source of these
muscle progenitor cells. We have concentrated our analysis on the
onset of myogenesis when Dmrt2 is strongly expressed in the
dermomyotome. In the absence of Dmrt2, the onset of Myf5
expression is affected. This depends on the epaxial enhancer [2,3],
which we show is regulated through Dmrt2 binding sites. This
enhancer is activated in the epaxial somite by signals from the
adjacent axial structures [6]. The requirement for Dmrt2 will
restrict this activation to the dermomyotome. Dmrt2 alone does
not direct ectopic expression of Myf5 outside the somite, indicating
that other factors also play a role in this restriction. Myf5 plays a
key role in the initiation of myogenesis, manifested by the
formation of the early epaxial myotome. The perduration of b-
galactosidase, either from a Myf5
nlacZ allele or from a Myf5-EpExt
regulated transgene, marks these first myogenic cells. When Myf5
expression is perturbed by the lack of Dmrt2, the formation of the
myotome is affected. In contrast, over-expression of Dmrt2
promotes Myf5 expression and myotome formation. Activation
of the myogenic differentiation programme is evidenced by
expression of the myogenic differentiation gene, myogenin, which
is delayed in somites in the Dmrt2 mutant and increased in the
early myotome when Dmrt2 is over-expressed. An important
aspect of myotome formation is the laying down of the basal
lamina that confines this somite compartment. In the absence of
Dmrt2, the expression of myogenic markers, such as myogenin, in
the myotome is more diffuse ventrally and this correlates with a
lack of laminin [25]. In contrast, when Dmrt2 is over-expressed, we
observed premature expression of laminin, associated with an
acceleration of myotome formation. Laminin is the ligand of a6b1
integrin, required for the formation of the myotome basal lamina.
Interestingly, a6b1 integrin is not expressed on myogenic cells
delaminating from the dermomyotome in Myf5 mutant mice, in
Figure 4. Dmrt2 is required for the maturation of the epaxial
somite, where Myf5 is first expressed. Whole mount in situ
hybridization of Dmrt2
+/2 (A) and Dmrt2
2/2 (B) embryos at E9.5, with a
Myf5 probe. (C–F) Sections of embryos shown in (A, B) at different axial
levels - left hand panels show more mature somites; immature somites
where the epaxial myotome is beginning to form are shown in right
hand panels. The onset of Myf5 expression is perturbed in the absence
of Dmrt2. (G, H) Whole mount in situ hybridization of Dmrt2
+/2 (G) and
Dmrt2
2/2 (H) embryos with a myogenin (Myog) probe, showing a
striking delay of myogenin expression in the absence of Dmrt2. (I, J)
Whole mount in situ hybridization of Dmrt2
+/2 (1) and Dmrt2
2/2 (J)
embryos showing Pax3 transcripts.
doi:10.1371/journal.pgen.1000897.g004
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form [39]. Since this early expression of Myf5 depends on the
epaxial enhancer, Dmrt2 lies genetically upstream of both this
integrin receptor and its laminin ligand (Figure 7).
The Pax3-Dmrt2-Myf5 regulatory cascade, identified by genetic
and molecular approaches, has consequences for the onset of
skeletal muscle formation, both in terms of the activation of the
myogenic regulatory programme and of the organisation of
myogenic cells and their progenitors within the somite. In Pax3
mutants, epaxial myogenesis occurs, however perturbations in
epaxial derivatives, such as deep back muscles, are observed [40].
Other Myf5 regulatory sequences control myotomal expression [2].
Pax3 also directly activates another Myf5 regulatory element at later
developmental stages [9]. This key factor therefore, directly or
indirectly influences different spatiotemporal aspects of myogenesis.
Expression of Dmrt2 is not limited to myogenic progenitors in the
epaxial domain, but is present throughout the developing
dermomyotome, where it may be implicated in maintaining this
epithelial structure [25]. We have recently identified Foxc2 as a gene
that is negatively regulated by Pax3 in the dermomyotome and that
promotes non-myogenic cell fates [41]. Identification of these
targets begins to reveal how Pax3 controls cell behaviour in the
somite before the determination of myogenic cells. Integration of
Pax3 targets into a regulatory network, comprising elements such as
thosediscussedinthis paper(Figure 7),is essentialforunderstanding
how such a key regulatory factor orchestrates the progression from
Figure 5. Dmrt2 binding sites in the Myf5 epaxial enhancer are essential for normal activity in vivo. (A) The sequence of the Myf5 epaxial
enhancer (EpExt), which drives early Myf5 expression in the epaxial domain of newly formed somites. TCF/LEF binding sites are boxed in green, the
Gli1 binding site in red, and four putative Dmrt2 binding sites in black. (B–D) EMSA performed with oligonucleotides conjugated with biotin,
containing Dmrt2 binding sites (1–4) as indicated in A, incubated with extracts of HEK293 cells, with (+) or without (2) a Dmrt2HA expression vector,
or oligonucleotides without biotin (dsDNA) (including mutated oligonucleotides; mut-dsDNA). In the supershift assay (D), binding was disrupted by
adding anti-HA (Monoclonal; Roche) to HA-tagged Dmrt2, whereas control anti-Flag antibody had no effect. The arrowheads show the binding
between the oligos and the tagged protein. NS; non-specific. (E, F) Transient transgenic analysis to examine the role of the Dmrt2 binding sites in the
Myf5 EpExt enhancer. The transgenes, containing mutated Dmrt2 binding sites1, 3, 4, showed reduced b-galactosidase activity in developing somites
with either the TK (E) or Myf5-BA (branchial arch) promoter region (F). The BA element that directs transgene expression to the branchial arches,
provides a positive control (arrowheads in F). Observations on transgenic embryos are summarised in Table 1.
doi:10.1371/journal.pgen.1000897.g005
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networks that control developmental processes is a major challenge,
taken up by the emerging field of systems biology.
Materials and Methods
Mice
Generation and genotying of Pax3
IRES-nlacZ/+, Pax3
GFP/+ [7],
Pax3
PAX3FKHR-IRESnlacZ/+ [31], Pax3
Pax3-En-IRESnlacZ/+ [9], Pax3
Cre/+
[33], PGK-Cre [32], Myf5
nlacZ/+ [42], Dmrt2
+/2, and Dmrt2
2/2 [25]
mice was carried out as previously described.
Screening
Pax3
GFP/+ mice were crossed with PGK-Cre transgenic mice to
obtain Pax3
GFP/+; PGK-Cre females, and these females were crossed
with Pax3
PAX3FKHR-IRESnlacZ/+ males to obtain embryos with one
Pax3
GFP allele and one floxed Pax3
PAX3FKHR-IRESnlacZ allele [31].
Somites were dissected from the interlimb region of E9.5 embryos.
The GFP positive cells were collected by FACs from Pax3
GFP/+
and Pax3
Pax3FKHR–IRESnlacZ/GFP mutant embryos. About 3.0610
5
cells were collected for RNA preparation, cDNA synthesis and
subsequent analysis using Affymetrix microarrays. Detailed
description of the microarray analysis will be published elsewhere
(Lagha and Sato, in preparation).
Plasmid construction and generation of transgenic mice
The mouse Dmrt2 cDNA (contains the complete coding region;
NM145831) was isolated by RT-PCR from cDNA of RNA
prepared from C57BL/6 mouse embryos at E9.5. The Dmrt2
cDNAs with or without a 39 sequence coding HA tag were
subcloned into pBS and pcDNA3 vectors for in situ hybridization,
electrophoresis mobility shift, and overexpression assays.
Figure 6. Overexpression of Dmrt2 accelerates myogenesis. (A) Luciferase assay in NIH3T3 cells with the Myf5EpExt fragment with (yellow
bars) or without (green bars) mutated Dmrt2 binding sites 1, 3, 4 (mutMyf5EpExt) as used in Figure 5, and increasing concentrations of a Dmrt2-
expression vector. As a positive control, b-catenin and Gli1 expression vectors were used (blue bars). Progressive increase in Dmrt2 expression, leads
to increased activation of the Myf5EpExt which is lost when Dmrt2 binding sites 1, 3, 4 are mutated. (B) The transgene for Dmrt2 conditional over-
expression, in which Cre recombination removes the CAT sequence leading to Dmrt2 and reporter Tomato red expression under the strong CAG
promoter. (C, C9,D ,D 9) Transgenic embryos, containing the CAG-floxedstop-Dmrt2-IRES-tdTomato (CAG-LSL-Dmrt2) transgene, crossed with PGK-Cre
mice (left in C, C9), and Pax3
Cre/+ mice (left in D, D9). Ectopic Dmrt2 expression is seen in PGK-Cre or Pax3
Cre/+ expressing embryos reflecting Cre
expression (arrowheads in C, D). (E–I) Whole mount in situ hybridization of transgenic control or Pax3-Cre activated embryos at E9.5. Myf5 (E.H) and
myogenin (F, I) expression are up-regulated in developing somites of embryos overexpressing the Dmrt2 transgene in Pax3 positive cells (arrowheads
in E, F) compared to controls (H, I). (G, J) Sections showing somites of control or activated Dmrt2 transgenic embryos at the same axial level, treated
by immunohistochemistry with a laminin antibody. Laminin is detected in the premature myotome, where it is not normally present at this
developmental stage. (arrowheads in G). (K, L) Whole mount X-gal staining of Myf5
nlacZ/+ embryos crossed onto the Dmrt2 expressing transgenic line,
with (K) or without (L) activation by Pax3-Cre, show perturbed location of b-galactosidase activity. This is shown on sections at the axial levels
indicated in K and L, in which Pax3 activation of the Dmrt2 transgene results in more extensive dermomyotome (arrows in K9,K 0) and early myotome
(K9) expression (not seen in the control (L9,L 0). Arrowheads indicate somite extent.
doi:10.1371/journal.pgen.1000897.g006
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located at 218 kb from the Dmrt2 gene (Dmrt2-286), or the
extended Myf5 epaxial enhancer (Myf5-EpExt, [6]), these sequences
were obtained by PCR from total DNA of E9.5, C57BL/6
embryos using KOD DNA polymerases (Novagen) and ligated
into pBS plasmids to lie 59 of TK-nlacZ or Myf5BA-nlacZ transgenic
sequences [43]. The primers used were as follows, Dmrt2-286-
Fwd; 59-GCAGCGGCCGCTATCAGGAATGAATTAGCTT-
GTTTCCCTCC-39, Dmrt2-286-Rev; 59- GCCACTAGTCTG-
GACCTCCTTTCCCCGATGCGTGCCCT-39, Myf5-EpExt-
Fwd; 59-GCAGCGGCCGCATGTAGACTCCTCACTTCTC-
GTTAGTAGA-39, Myf5-EpExt-Rev; 59- GCCACTAGTGGA-
TCCCGGCTGGCAAATGTTTGGTTCCCT-39.
Transgenes with mutated Pax3 or Dmrt2 binding sites were
created with the QuikChange Multi Site-Directed Mutagenesis kit
(Stratagene). The Myf5EpExt-TK fragment was digested with NheI
and NcoI, and ligated into the pGL4 vector (Promega) in front of
the luciferase reporter for transactivation assays.
For transgenic expression of Dmrt2, the HindIII and BamHI
fragment digested from the pBS-CAG-floxedCAT vector [44], the
HindIII and XbaI fragment digested from pBS-Dmrt2, and the
XbaI and BamHI fragment digested from the pCMVTnT-IRES2-
tdTomato-pA vector (pCMVTnT; Promega, pIRES2; Clontech,
tdTomato; a gift from Dr. Tsien) were all ligated together to make
the pBS-CAG-floxedCAT-Dmrt2-IRES2-tdTomato vector (pBS-CAG-
LSL-Dmrt2). pBS-Dmrt2-286-TK-nlacZ, pBS-Myf5EpExt-TK-nlacZ,
pBS-Myf5EpExt-BA-nlacZ and pBS-CAG-LSL-Dmrt2 vectors were
linearized to produce transgenic mice according to standard
techniques. The primers used for genotyping of CAG-LSL-Dmrt2
mice were as follows, F502; CTCCGGAGGCAGCAGGCC-
ACAG, R620; ATGCTTTTGGCCAGCAAACTCG; R794;
CGCGATGTCCCAAATGGACCTAA (wildtype; 293 bp, trans-
gene; 119 bp).
For BAC transgenic analysis, a BAC containing Dmrt2 genomic
DNA (2150 kb/+50 kb: clone RP24-290E12 purchased from
BACPAC resources center, CHORI) was used for targeting with
an nlacZ reporter into the ATG site of Dmrt2. The Dmrt2 BAC with
a mutated Pax3 binding site in the 286 bp sequence was created
using the fragment from the transgene with the mutated Pax3
binding site in Dmrt2-286. All BAC recombineering were
performed with SW105 and SW106 strains [45].
Whole mount staining of embryos and
immunohistochemistry
Whole mount in situ hybridization analyses and X-gal staining
were performed as previously described [15]. For double detection
of b-galactosidase (b-gal) from a Pax3 nlacZ allele and Dmrt2
transcripts, the former was visualized by Red-gal (Sigma), and the
latter using a digoxigenin (DIG)-labeled probe visualized with BM
purple (Roche). For immunohistochemistry of laminin, the
antibody against laminin (Chemicon; AL-4 clone) was used as
described [39].
Electrophoretic mobility shift assays (EMSA)
EMSA was performed using the LightShift Chemiluminescent
EMSA kit (Thermo Fisher Scientific). Protein extracts containing
Pax3 or Dmrt2 protein were prepared from HEK293 cells
transfected with pcDNA3-Pax3 [46] or pcDNA3-Dmrt2HA. Cells were
then lysed on ice in extraction buffer (15 mM Tris pH 7.4;
containing protease inhibitor cocktail (Roche)) supplemented with
0.5% NP40. Lysates were centrifuged at 20006g for 5 min at 4uC
and the supernatant was stored in 25% glycerol at 280uC until
ready for use. The 59-biotin-conjugated oligos and unlabeled probes
used were as follows, Pax3BS1; 59-CTTGTTTCCCTCCTGTA-
AGTGATCC-39, Pax3BS2; 59-CTGTGGTGTGTGACTAA-
TGGAGTGC-39, Pax3BS3; 59-CTCTCAGGGCTGGTTTAAG-
ACTCA-39, Pax3BS4; 59-CATAGCAGGGACACAGTAAA-
GCCAC-39, mutPax3BS2; 59- CTGTGGTGACGTCTAAAT-
GGAGTGC-39, Dmrt2BS1; 59-CTGTTTCCTAGTGTAGAT-
CT-39, Dmrt2BS2; 59- GATTTTACAACGTGTGCCGC-39,
Dmrt2BS3; 59-TCTGTTTTTCCTGTAACCTC-39, Dmrt2BS4;
59-TCTCTGTAGCTCTCATGTAAA-39, mutDmrt2BS1; 59-
CTGTTTCCTTGTTTTGATCT-39, mutDmrt2BS3; 59-TCT-
GTTTTTCCTTTTATCTC-39, mutDmrt2BS4; 59-TCTCTT-
TTGCTCTCATTTTAA-39. Sense and anti-sense strands were
synthesized and 40 fmol biotin-labeled double-stranded DNA was
mixed with 1 mg protein from a HEK293 cell extract. Gel mobility
shift assays and hybridization were performed according to the
instructions of Invitrogen, using 6% DNA retardation gels
(Invitrogen).
Chromatin Immunoprecipitation (ChIP)
ForChIPexperiments,somiteswerecollectedfromE9.5embryos
with heads, neural tubes and internal organs removed. These
samples were mechanically digested through a syringe and
dissociated cells were fixed with 1% formaldehyde at room
temperature for 10 min. The ChIP procedure was performed
according to an enzymatic digestion protocol (ChIP-IT Express;
ActiveMotif) with Pax3 antibody raised from Rabbit (ActiveMotif
and Geneka; Bajard et al., 2006 and Lagha et al., 2008) or normal
Rabbit serum (Sigma) as a control. Input DNA and immunopre-
cipitated DNA were analyzed by PCR. The sequences of primers
were designed as follows. The Dmrt2-18 kb conserved region
(286 bp) Fwd; 59-GCTTGTTTCCCTCCTGTAAGT-39,R e v ;
59- GTGTAGGATCTGTGGCTTTAC-39 and the Dmrt2+20 kb
control conserved region (+20 kb) Fwd; 59-GGTTCTCATAATT-
TACATGCT-39, Rev; 59- TCCAACATCTGATTGTACTTA-39.
Luciferase assay
For luciferase assays, pGL4-Myf5EpExt vectors were transfected
into NIH3T3 cells together with a pRL-TK plasmid (Promega; for
Figure 7. A schematic representation of the regulatory network
presented in this paper. Direct targets are shown in heavy type.
Indirect targets are indicated by a discontinuous arrow. The myogenin
promoter depends on a critical Ebox [47,48] targeted by Myf5. a6b1
integrin expression depends on Myf5, in cells entering the myotome
[39]. This receptor interacts with Laminin1 as a ligand, leading to
formation of the basement membrane of the myotome. Laminin
expression is modulated by Dmrt2 (see also [25]).
doi:10.1371/journal.pgen.1000897.g007
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vectors were kindly provided by Dr. S. Brunelli). Transfected cells
were cultured for 24 hours, and subjected to luciferase assays using
the Dual-Luciferase Reporter Assay System (Promega).
Supporting Information
Figure S1 The expression of Dmrt2 is controlled by Pax3. Whole
mount in situ hybridization with a Dmrt2 probe of Pax3
GFP/+ (left)
and Pax3
GFP/nLacZ (right) embryos at E9.25. The number of somites
(ss, somite stage) is indicated on each panel. When Pax3 is absent,
Dmrt2 transcripts are reduced, notably in the hypaxial and epaxial
domains where Pax7 is not expressed.
Found at: doi:10.1371/journal.pgen.1000897.s001 (0.58 MB TIF)
Figure S2 Dmrt2 BAC transgenics show that the conserved Pax3
binding site is important for regulation of Dmrt2 expression in the
somite. A BAC containing Dmrt2 genomic DNA (2150 kb/
+50 kb), including the conserved 286 bp Dmrt2 element, (clone
RP24-290E12 purchased from BACPAC resources center,
CHORI) was targeted with an nlacZ reporter. (A) A transgenic
embryo (E8.5) with this BAC shows dermomyotome expression.
(B) When the Pax3 binding site is mutated in the context of this
BAC, transgene expression in the somite is severely reduced. In
(A), a transgenic line is shown. In (B), a transitory transgenic (F0)
embryo is shown, where residual expression is observed. Two lines
showed no expression (see Table 1).
Found at: doi:10.1371/journal.pgen.1000897.s002 (1.47 MB TIF)
Figure S3 Ubiquitous overexpression of Dmrt2 shows Myf5
upregulation only in somites. Transgenic embryos, containing the
CAG-floxedstop-Dmrt2-IRES-tdTomato (CAG-LSL-Dmrt2) transgene,
crossed with PGK-Cre mice (left). Whole mount in situ hybridization
of transgenic control or PGK-Cre activated embryos at E9.5. Myf5
expression is up-regulated in developing somites of embryos where
Dmrt2 is overexpressed (arrowhead in left panel) compared to
controls (right).
Found at: doi:10.1371/journal.pgen.1000897.s003 (0.82 MB TIF)
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